* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download VirionHealth - University of Warwick
Survey
Document related concepts
Bioterrorism wikipedia , lookup
2015–16 Zika virus epidemic wikipedia , lookup
Hepatitis C wikipedia , lookup
Ebola virus disease wikipedia , lookup
Neonatal infection wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
West Nile fever wikipedia , lookup
Marburg virus disease wikipedia , lookup
Hepatitis B wikipedia , lookup
Orthohantavirus wikipedia , lookup
Middle East respiratory syndrome wikipedia , lookup
Herpes simplex virus wikipedia , lookup
Swine influenza wikipedia , lookup
Transcript
VirionHealth™ Therapeutic RNA Antiviral for Influenza & Respiratory Viruses VirionHealth Ltd is a spinout company from the University of Warwick with a prophylactic and therapeutic platform targeting a wide range of respiratory diseases. Its lead candidate, FluPro™, is at the preclinical stage, with in vivo data indicating efficacy against multiple respiratory viruses and, in particular, against all influenza A strains (which include seasonal flu and potential pandemic threats such as H5N1 and H7N9). TARGET MARKETS INVENTION FluPro is a treatment for anyone vulnerable to infection FluPro is a RNA-based antiviral biologic active against a by a variety of respiratory viruses and, especially, wide variety of respiratory viruses and, in particular, all influenza. Market segments include: influenza A viruses. It is delivered by a non-infectious Healthcare providers seeking additional treatments influenza virus particle and combats infections in to seasonal flu vaccines and improved, lower cost several different ways. It is a prophylactic with outcomes for vulnerable patients young and old. therapeutic effects. It protects against all influenza A viruses using a small RNA molecule (DI244) to block the replication of infectious virus Governments seeking treatment options for seasonal influenza and pandemic threats. General public seeking prophylactic treatments when potentially exposed to influenza outbreaks. It protects against other respiratory viruses, including influenza B and viruses like respiratory syncytial virus (RSV) by inducing interferon production in the respiratory tract PATENTS & PUBLICATIONS It allows a specific immune response against any infecting virus by limiting virus replication to prevent disease while allowing natural immunity to develop WO2007135420 Defective interfering virus; priority date: May 2007; patent status: granted in AU, CN, UK, IN & US; under examination in CA, EU, IN divisional, US continuation. KEY BENEFITS A prophylactic with therapeutic effects Single, broad spectrum treatment for multiple respiratory viruses and especially influenza Retains activity and efficacy regardless of antigenic shift and drift with no annual re-engineering needed for seasonal influenza Potential to address pandemic threats from new influenza A viruses (e.g. H5N1 & H7N9) Immediacy of protection and reduced severity of clinical disease in the elderly and immunocompromised Therapeutic effect reduces disease from an established infection Less frequent and lower dose regimen (a single, small intranasal weekly dose) compared with current antiviral drugs (twice daily dose for several days) delivered direct to the respiratory tract Long term stability in standard industry storage conditions with the potential for stockpiling Emergence of extremely low resistance calculated to be Two large patent families form the IP asset base. WO2010067109 Anti-viral protection with viruses containing defective genome segments; priority date: Dec 2009; patent status: Granted in EU (14 designated states); under examination in AU, CA, CN, IN & USA. 1. 2. 3. 4. Dimmock, N. J. et al (2012) Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI virus and oseltamivir. Antivirus Research 96, 376 Scott, P. D. et al. (2011) Defective interfering virus protects elderly mice from influenza. Virology J 8, 212 Easton, A. J. et al (2011) A novel broad-spectrum treatment for respiratory virus infections: influenzabased defective interfering virus provides protection against pneumovirus infection in vivo. Vaccine 29, 2777 Dimmock, N. J. et al (2008). Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral. J Virol 82, p8570 CONTACT Substantial further information is available. For partnering or investment enquires please contact Dr Laura Lane, Tel: +44 (0)2476 575745 or +44 (0)7880 175404 or email: [email protected]. Warwick Ventures Ltd, is the technology commercialisation company at the University of Warwick.